Loading Tests
| Test code | Test Name | Method | TAT | Segment | aaa | a | a | ddd | fff | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MM1836 | HLA hypersensitivity (B*15;02) to Carbamazepine & Phenytoin | PCR Sequencing | 9 Days | Transplant Immunology | |||||||||||
| ME1018 | CMV Quantitative | RT-PCR | 5 Days | Transplant Immunology | haematology | cancer | Cytomegalovirus | ||||||||
| ME1456 | CMV DNA Qualitative | PCR | 5 Days | Transplant Immunology | haematology | cancer | Cytomegalovirus | ||||||||
| MD1024 | HLA DSA (Donor Specific IgG Antibodies), Class I & II (for 1 patient & 1 donor) If there is extra donor than the seperate accessioning will be done and than will be again Rs 12499, total amount is 24999 | Luminex X-Map technology | 5 Days | Transplant Immunology | haematology | cancer | human leukocyte antigen | transplant | |||||||
| AD1686 | EBV IgG antibody to Viral capcid antigen(VCA) | Immunofluorescence Assay | 5 Days | Transplant Immunology | |||||||||||
| HB896 | EBV IgM antibody to Viral capsid antigen(VCA) | Enzyme immunoassay | 5 Days | Transplant Immunology | |||||||||||
| AK1233 | P-ANCA Specific | Enzyme immunoassay | 5 Days | Transplant Immunology | |||||||||||
| AK1232 | C-ANCA Specific | Enzyme immunoassay | 5 Days | Transplant Immunology | |||||||||||
| MY1697 | HLA - B5 (B*51/52) | Reverse SSOP - Luminex | 4 Days | Transplant Immunology | haematology | cancer | human leukocyte antigen | transplant | |||||||
| IA1859 | EBV (DAKO) | IHC | 4 Days | Transplant Immunology | oncology | epstein | |||||||||
| ME1835 | Epstein-Barr Virus (EBV) DNA Quantitative | RT-PCR | 3 Days | Transplant Immunology | |||||||||||
| XA1756 | Everolimus | Liquid chromatography–mass spectrometry | 3 Days | Transplant Immunology | |||||||||||
| AL1600 | Cytomegalo Virus (CMV) - IgG | Immunoturbidometry | 3 Days | Transplant Immunology | |||||||||||
| AL1340 | C3&C4 Complement panel | Immunoturbidimetry | 3 Days | Transplant Immunology | |||||||||||
| AB1554 | Cytomegalovirus (CMV) Antibodies Panel, IgG & IgM | CLIA | 3 Days | Transplant Immunology | |||||||||||
| AL2183 | C4 Complement | Immunoturbidimetry | 3 Day | Transplant Immunology | |||||||||||
| MA1210 | HLA A B C DR DQ (Low resolution) | PCR | 12 Days | Transplant Immunology | haematology | cancer | human leukocyte antigen | transplant | |||||||
| MA1023 | HLA A B DR Typing (Low resolution) | PCR | 12 Days | Transplant Immunology | haematology | cancer | human leukocyte antigen | transplant | |||||||
| NA1211 | HLA Typing Advance (A,B,C,DR,DQ)- Donor Only | NGS (High Resolution) | 12 Days | Transplant Immunology | haematology | cancer | human leukocyte antigen | transplant | |||||||
| NA1364 | DR/DQ | NGS (High Resolution) | 12 Days | Transplant Immunology | haematology | cancer | |||||||||
| MA1213 | Patient only, HLA typing ( High Resolution) | Next Generation Sequencing | 12 Days | Transplant Immunology | haematology | cancer | |||||||||
| AW1904 | C1 Esterase Inhibitor, C1 Inhibitor, Quantitative | Radial Immunodiffusion | 10 Days | Transplant Immunology | |||||||||||
| AD1212 | Phospholipase A2 Receptor Antibody (PLA2R) Qualitative | Immunofluorescence Assay | 10 Days | Transplant Immunology | |||||||||||
| MJ1941 | Prader- Wili Syndrome | MS-PCR | Sample By Thursday, Report 14 Days | Rare and Inherited | brain | ||||||||||
| AD1731 | NMO with MOG profile Antibody | Immunofluorescence Assay | Sample By Sat/Wed, Report In 7 Days | Rare and Inherited | |||||||||||
| AB1780 | SHBG | Chemiliminescent Immunoassay | Sample By Sat And Wed, Report In 3 Days | Rare and Inherited | |||||||||||
| OA1728 | Multiple Sclerosis Panel- Comprehensive (Albumin-CSF & Serum, IgG-CSF & Serum, Oligoclonal Band, CSF Index and MAG Antibody) | Multiple Technologies | Sample By Sat And Wed, Report 8 Days | Rare and Inherited | brain | ||||||||||
| MI1702 | DMD Duchenne Muscular Dystrophy | Multiplex PCR | Sample By Last Sat Of Month, Report 10 Days | Rare and Inherited | brain | ||||||||||
| IA1167 | Immunohistochemistry, ACTH | Immunohistochemistry | 9 Days | Rare and Inherited | oncology | ||||||||||
| BT1216 | IMD Panel, Quantitative, Blood | Tandem Mass Spectrometry | 7 Days | Rare and Inherited | |||||||||||
| AK1691 | Scl-70 (Scleroderma) Antibody | Enzyme immunoassay | 7 Days | Rare and Inherited | |||||||||||
| NA1416 | Wilson Disease - ATP7B Gene Sequencing | Next Generation Sequencing | 6 Weeks | Rare and Inherited | brain | ||||||||||
| NA1412 | Gene analysis TSC1 & TSC2 | Next Generation Sequencing | 6 Weeks | Rare and Inherited | oncology | ||||||||||
| NA1613 | Skeletal Dysplasia | Next Generation Sequencing | 5 Weeks | Rare and Inherited | brain | ||||||||||
| MC2110 | FBN1 Gene Sequencing & Del/Dup | MLPA | 4 Weeks | Rare and Inherited | Cardiology | Cardiac | heart | marfan | |||||||
| IA1891 | B-Cell Specific Activator Protein (PAX-5) | IHC | 4 Days | Rare and Inherited | oncology | ||||||||||
| IA1788 | WT1 (WILMS TUMOR) | IHC | 4 Days | Rare and Inherited | oncology | ||||||||||
| IA1429 | Vimentin (EP21 Rabbit Monoclonal) | IHC | 4 Days | Rare and Inherited | oncology | ||||||||||
| IA1433 | NSE | IHC | 4 Days | Rare and Inherited | oncology | ||||||||||
| NA1367 | Clinical Exome Sequencing Panel | Next Generation Sequencing | 35 Days | Rare and Inherited | oncology | wes | wgs | ||||||||
| BB1330 | Angiotensin Converting Enzyme (ACE) | Spectrophotometry | 3 Days | Rare and Inherited | |||||||||||
| MA1022 | HLA - B27, Qualitative | PCR | 3 Days | Rare and Inherited | haematology | cancer | human leukocyte antigen | transplant | |||||||
| AK1685 | Galactomannan (Aspergillus antigen) | Enzyme immunoassay | 3 Days | Rare and Inherited | |||||||||||
| AH1244 | Anti - dsDNA Antibody | ELISA | 3 Days | Rare and Inherited | |||||||||||
| AP1608 | NT-PRO BNP | Electrochemiluminescence Assay | 3 Days | Rare and Inherited | |||||||||||
| AO1234 | Anti Cyclic Citrullinated Peptide; ANTI CCP | Chemiluminescent Microparticle Immunoassay | 3 Days | Rare and Inherited | |||||||||||
| AB1159 | IGF - I & Growth hormone Panel | Chemiliminescent Immunoassay | 3 Days | Rare and Inherited | |||||||||||
| AB1341 | B-Type Natruiretic peptide (BNP) | Chemiliminescent Immunoassay | 3 Days | Rare and Inherited | |||||||||||
| MV1644 | Sanger mutation confirmation upto 2 mutations | Sanger | 23 Days | Rare and Inherited | |||||||||||
| AH1730 | RNA Polymerase III Antibody | ELISA | 18 Days | Rare and Inherited | |||||||||||
| MN1932 | Hereditary Hemochromatosis DNA Mutation analysis | Sequencing | 15 Days | Rare and Inherited | |||||||||||
| MM2192 | LHON Mitochondrial Mutation Detection | PCR Sequencing | 15 Days | Rare and Inherited | |||||||||||
| AH1366 | ADAMTS 13 activity with reflex to inhibitor | Enzyme immunoassay | 15 Days | Rare and Inherited | |||||||||||
| ND1683 | MYD88, Mutation Analysis | DNA Sequencing | 15 Days | Rare and Inherited | haematology | cancer | |||||||||
| MX1651 | HDV RNA Detection | PCR + hybridisation | 13 Days | Rare and Inherited | |||||||||||
| MM1488 | Spinal Muscular Atrophy Microdeletion- SMN1 | PCR Sequencing | 10 Days | Rare and Inherited | brain | ||||||||||
| NA1569 | pulmoCORE 5 Gene Panel EGFR, BRAF, c-MET, ALK & ROS1 | Next Generation Sequencing | 9 Days | onCORE | |||||||||||
| TS748 | Any 1 IHC marker | IHC | 4 Days | onCORE | |||||||||||
| P00078 | ALK IHC + ROS1 IHC | As mentioned in individual tests | 4 Days | onCORE | |||||||||||
| NA1413 | Mammaprint | Next Generation Sequencing | 20 Days | onCORE | |||||||||||
| P00142 | Mammaprint + Genetic Counselling | Next Generation Sequencing | 20 Days | onCORE | |||||||||||
| P00120 | EGFR+ ALK+ ROS-1+ MET+ BRAF+ AlK IHC Reflex | Multiple Technologies | 18 Day | onCORE | |||||||||||
| ME1969 | JEV-Japanese Encephalitis Virus | Real Time PCR | Sample By Wed, Report In 1 Week | neuroCORE | brain | ||||||||||
| OA2111 | Myasthenia Gravis Profile (AChR, ASKA, MUSK) | Multiple Technologies | Sample By Sat, Reprort 5 Days | neuroCORE | brain | ||||||||||
| A22156 | Paraneoplastic Disorder- PNMA2 Antibody | Immunoblot | Sample By Mon, Report Next Day | neuroCORE | brain | ||||||||||
| AN1814 | MuSK (Muscle Specific Kinase) Antibody | Radioimmunoassay | Sample By Mon, Report In 4 Days | neuroCORE | |||||||||||
| AD1494 | NMDA Receptor antibody | IFA | Sample By Mon And Thursday, Report In 3 Days | neuroCORE | brain | ||||||||||
| BD1817 | Autoimmune encephalitis panel-1 | IFA | Sample By 1St Or 3Rd Saturday, Report 3 Days | neuroCORE | |||||||||||
| AN1368 | Acetylcholine Receptor (ACHR) Binding Antibody | Radioimunoassay | 7 Days | neuroCORE | |||||||||||
| AA2021 | Ganglioside Gq1b Antibody,IgG | Immunoassay | 6 Weeks | neuroCORE | |||||||||||
| NA2130 | Congenital Muscular Dystrophy Panel | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| NA2129 | Neurofibromatosis- NF1 & NF2 | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| AV1825 | Extractable Nuclear Antigens (ENA), Qualitative Profile | Line Immunoassay | 5 Days | neuroCORE | |||||||||||
| AD1166 | Anti-Smooth Muscle Antibody (ASMA) | Immunofluorescence Assay | 5 Days | neuroCORE | |||||||||||
| A22089 | Neuronal (Paraneoplastic) Autoantibodies Profile | Immunoblot | 5 Days | neuroCORE | |||||||||||
| IA1850 | SOX 11 | Immunohistochemistry | 4 Days | neuroCORE | oncology | ||||||||||
| IA1790 | SMA | IHC | 4 Days | neuroCORE | oncology | ||||||||||
| AK1831 | Glutamic Acid Decarboxylase (GAD) IgG Antibodies | Enzyme immunoassay | 3 Days | neuroCORE | |||||||||||
| AK1828 | ASCA (Anti Saccharomyces Cerevisiae Antibody), IgA & IgG Panel | Enzyme immunoassay | 10 Days | neuroCORE | |||||||||||
| P00106 | Histopathology, Kidney Biopsy Panel (LM+IF) | As mentioned in individual tests | 6 Days, Verbal Report In 3 Days | nephroCORE | |||||||||||
| P00109 | HISTOPATHOLOGY, TRANSPLANT KIDNEY BIOPSY PANEL (LM+IF) | As mentioned in individual tests | 6 Days, Verbal Report 3 Days | nephroCORE | |||||||||||
| P00107 | Histopathology, Native Kidney Biopsy Panel (LM+IF+TEM) | As mentioned in individual tests | 6 Days (Lm+If), Verbal Report 3 Days (Lm +If), 14 Days (Em) | nephroCORE | |||||||||||
| PA1617 | Histopathology, Kidney Biopsy (LM) | Light Microscopy | 6 Days | nephroCORE | |||||||||||
| PE1618 | Histopathology, Direct Immunofluorescence (DIF), Kidney Biopsy | Fluoroscence Microscopy | 6 Days | nephroCORE | |||||||||||
| P00110 | Histopathology, Transplant Kidney Biopsy Panel (LM+IF+TEM) | As mentioned in individual tests | 5 Days (Lmrlr) 14 Days (Em), Verbal R€Port 3 Day (Lm+Lt) | nephroCORE | |||||||||||
| P00112 | HISTOPATHOLOGY, KIDNEY BIOPSY SECOND OPINION | Light Microscopy | 4 Days, Verbal Report 3 Days | nephroCORE | |||||||||||
| PA1812 | COREprime (LM) | Light Microscopy | 3 Days, Verbal In 1 Day | nephroCORE | |||||||||||
| PF1620 | Transmission Electron Microscopy (TEM) | TEM | 14 Days | nephroCORE | |||||||||||
| NA2108 | nephroCORE HLA high resolution (A,B,C,DR,DQ) | Next Generation Sequencing | 10 Days | nephroCORE | |||||||||||
| AO1378 | Cyclosporine, C0 | Chemiluminescence | 1 Day | nephroCORE | |||||||||||
| OA2030 | Histopathology, direct immunofluoroscence DIF, Conjunctival biopsy panel: C3, C1q, IgA, IgG, IgM | Cryoprocessing, Fluorescence Microscopy | 7 Days | histoCORE | |||||||||||
| OA2067 | Skin Biopsy, Direct Immuno-Fluoroscence (DIF) | Cryoprocessing, Fluorescence Microscopy | 7 Days | histoCORE | |||||||||||
| PA1143 | Bone marrow Biopsy | Microscopy | 5 Days | histoCORE | haematology | cancer | |||||||||
| IA2073 | IgG4, IHC with Interpretation | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1839 | BCL6 | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1132 | CD2 (EP222 Rabbit Monoclonal) | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1873 | MUM 1 | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1785 | CD10 | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1901 | SAT B2 (EP281 Rabbit Monoclonal) | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1794 | DOG-1 | IHC | 4 Days | histoCORE | oncology | ||||||||||
| IA1857 | CD8A | IHC | 4 Days | histoCORE | oncology | ||||||||||
| HA1057 | Histopathology, Biopsy, Small Specimen | Histopathology | 3 Days | histoCORE | oncology | ||||||||||
| IA1655 | CORExpert Panel | IHC | 10 Days | histoCORE | oncology | ||||||||||
| OA1722 | Thrombophilia Profile (Protein C, Functional *Protein S, Functional *Antithrombin Activity Functional *Factor V Leiden Mutation *Prothrombin Gene Mutation *MTHFR gene mutation) | Electromechanical & Photo-optical Clot Detection, PCR | Sample By Saturday Or Wed, Report In 6 Days | hemaCORE | |||||||||||
| ME1309 | ALPHA THALASSEMIA MUTATION DETECTION | PCR, MLPA | Sample By Sat, Report In 10 Days' | hemaCORE | |||||||||||
| OA1492 | Thrombophilia Panel-Basic (Lupus Anticoagulant, Activity of Protein C, Protein S, at III and APCR, ACA-IgG/IgM) | Multiple Technologies | Sample By Sat, Report 4 Days | hemaCORE | brain | ||||||||||
| ME1637 | FLT3 Gene Mutation Quantitative Monitor | RT-PCR | Sample By Sat / Wed 11 Am; Report In 7 Days | hemaCORE | |||||||||||
| AF1075 | Beta - 2 - Microglobulin, Serum | Nephelometry | Sample By Mon/Wed/Fri Report Same Day. After 1 Pm Report Next Day | hemaCORE | oncology | ||||||||||
| AF1042 | Kappa/Lambda free Light Chain | Nephelometry | Sample By Mon/Wed/Fri Report Same Day. After 1 Pm Report Next Day | hemaCORE | haematology | cancer | |||||||||
| BH1074 | Protein electrophoresis, Serum | Gel Electrophoresis | Sample By Mon/Wed/Fri Report Same Day. After 1 Pm Report Next Day | hemaCORE | |||||||||||
| P00140 | Multiple myeloma diagnostic panel | As mentioned in individual tests | Sample By Mon/Wed/Fri Report Same Day. After 1 Pm Report Next Day | hemaCORE | haematology | cancer | |||||||||
| BH1059 | Multiple Myeloma comprehensive panel Quantitative | Agarose Gel Electrophoresis | Sample By Mon/Wed/Fri Report Same Day. After 1 Pm Report Next Day | hemaCORE | haematology | cancer | |||||||||
| MR1442 | T cell gene rearrangement | PCR/ Fragment analysis | Sample By Friday, Report In 13 Days | hemaCORE | |||||||||||
| AO1328 | Tacrolimus | CMIA | Same Day, Sample After 5 Pm, Report Next Day | hemaCORE | |||||||||||
| AO1231 | CA 125; Ovarian Cancer Marker | CMIA | Report Same Day, After 1 Pm Report Next Day | hemaCORE | |||||||||||
| P00014 | Cytogenetics (Karyotyping), Leukemia Advance (Flowcytometry) | As mentioned in individual tests | As Mentioned In Individual Tests | hemaCORE | haematology | cancer | |||||||||
| ME1985 | IKZF1 deletions (B- or T-ALL) | Real-time PCR | 8 Days | hemaCORE | |||||||||||
| MS1298 | VNTR Chimerism study | PCR-VNTR | 8 Days | hemaCORE | haematology | cancer | |||||||||
| ME1010 | Jak 2 Exon 12-15 | Mutation Analysis | 8 Days | hemaCORE | haematology | cancer | |||||||||
| P00071 | Erythropoietin (EPO)+Jak 2 Exon 12-15 | Multiple Technologies | 8 Days | hemaCORE | |||||||||||
| YB1157 | Ewing's Sarcoma | FISH | 8 Days | hemaCORE | haematology | cancer | |||||||||
| YB1093 | n MYC gene amplification | FISH | 8 Days | hemaCORE | haematology | cancer | |||||||||
| YB1663 | IgH gene rearrangement | FISH | 8 Days | hemaCORE | haematology | cancer | |||||||||
| MA1003 | BCR – Abl Kinase Domain Mutations | Mutation Analysis | 7 Days | hemaCORE | haematology | cancer | Philadelphia chromosome | chronic myelogenous leukemia | CML | ||||||
| ME1015 | FLT3 | Mutation Analysis | 7 Days | hemaCORE | haematology | cancer | FMS-like tyrosine kinase | ||||||||
| YB1869 | Monosomy7 | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1271 | Del 5q | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1314 | X Y Chimerism | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1156 | MLL | FISH | 7 Days | hemaCORE | haematology | cancer | Acute Myeloid Leukemia | ||||||||
| YB1072 | Multiple Myeloma del17p, t(14;20), Monosomy 1,t(14;16), t(11;14), del13q and t(4;14) | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1318 | Multiple Myeloma (del13q14.3,t(4;14),t(14;16),t(11;14) | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1287 | Inv (16) (CBFB/MYH11) | FISH | 7 Days | hemaCORE | haematology | cancer | inversion | ||||||||
| YB1286 | t(8;21)(AML1/ETO) | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1950 | t(12;21) ETV6/RUNX1(TEL/AML1) | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1151 | ALL Panel(BCR-ABL;TEL/AML;MLL;E2A(1;19) | FISH | 7 Days | hemaCORE | haematology | cancer | acute lymphoblastic leukemia | ||||||||
| YB1263 | 13q deletion | FISH | 7 Days | hemaCORE | haematology | cancer | Monosomy 13q | myelodysplastic | acute myeloid leukaemia | ||||||
| YB1292 | Trisomy 12 | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1289 | 6q deletion | FISH | 7 Days | hemaCORE | haematology | cancer | acute lymphoblastic leukemia | ALL | NHL | Hodgkin | |||||
| P00069 | Double/Triple hit lymphoma (blood and BM) | As mentioned in individual tests | 7 Days | hemaCORE | |||||||||||
| MW1452 | t(1;19) (q23;p13.3); TCF3-PBX1(E2A-PBX1), PCR Qualitative | Real Time PCR | 6 Days | hemaCORE | haematology | cancer | |||||||||
| YB1732 | hemaCORE MDS extended 8 markers (Monosomy 5/ Del 5q, Monosomy 7/ Del 7q, Trisomy 8, Del20q, Monosomy 13/ Del 13q (RB1), Monosomy 17/ Del 17p (TP53), MLL Break apart (BA)/ 11q23 realted translocation, MECOM Break apart (BA)/ Inv-3) | FISH | 6 Days | hemaCORE | |||||||||||
| YB1642 | RARA translocation | FISH | 6 Days | hemaCORE | |||||||||||
| P00017 | AML panel with MLL by FISH (PML/RARa,AML/ETO,Inv 16 and MLL gene | FISH | 6 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | ||||||||
| YB1385 | CLL (del 6q,del 11q,del13q,Trisomy12,del17p) | FISH | 6 Days | hemaCORE | haematology | cancer | Chronic Lymphocytic Leukemia | ||||||||
| MN1523 | Beta Thalassemia-XMN polymorphism | Sequencing | 5 Weeks | hemaCORE | |||||||||||
| P00121 | Jak 2 Exon 14 to 12 (Reflex Testing) | Mutation Analysis | 5 Days And 10 Days | hemaCORE | haematology | cancer | |||||||||
| ME1951 | t(5;12)PDGFRB/ETV6 | RT-PCR | 5 Days | hemaCORE | haematology | cancer | |||||||||
| ME2019 | AML/ETO Quantitative | RT-PCR | 5 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | fusion | oncoprotein | ||||||
| ME1371 | Inv (16) Quantitative | RT-PCR | 5 Days | hemaCORE | haematology | cancer | inversion | ||||||||
| ME1009 | Jak 2 Exon 14 | RT-PCR | 5 Days | hemaCORE | haematology | cancer | |||||||||
| ME1182 | Prothrombin Gene Mutation Analysis | Real Time PCR | 5 Days | hemaCORE | |||||||||||
| ME1162 | Factor V Leiden Mutation Anaysis ( MTHFR gene) | Real Time PCR | 5 Days | hemaCORE | |||||||||||
| MA1384 | FIP1 L1 -PDGFRa | PCR | 5 Days | hemaCORE | haematology | cancer | Feline infectious peritonitis | ||||||||
| MA1027 | ALL Multiplex (BCR-ABL,MLL-AF9,MLL-AF4,MLL-EN6, t(1;19) & t(12;21)) | Multiplex PCR | 5 Days | hemaCORE | haematology | cancer | acute lymphoblastic leukemia | ||||||||
| P00083 | Hematopoietic Neoplasm Panel Peripheral smear,Bone marrow aspirate and Bone marrow biopsy including iron stain & special stain | Microscopy | 5 Days | hemaCORE | haematology | cancer | |||||||||
| YB1073 | MDS | FISH | 5 Days | hemaCORE | haematology | cancer | Myelodysplastic | ||||||||
| YB1014 | PML Rara | FISH | 5 Days | hemaCORE | haematology | cancer | |||||||||
| YB1004 | BCR - Abl FISH (t (9;22)) | FISH | 5 Days | hemaCORE | haematology | cancer | Philadelphia chromosome | chronic myelogenous leukemia | CML | ||||||
| YB1852 | 11Q (ATM) | FISH | 5 Days | hemaCORE | haematology | cancer | CLL | chronic | Chronic Lymphocytic Leukemia | ||||||
| NA1522 | Beta Thalassemia mutation study | Next Generation Sequencing | 4 Weeks | hemaCORE | haematology | cancer | |||||||||
| IA1690 | CD61 | Immunohistochemistry | 4 Days For Block 6 Days For Tissue | hemaCORE | |||||||||||
| MU1310 | AML Multiplex- Basic (BCR - ABL, PML RaRa, AML ETO, INV 16, NPM1, FLT3,c-KIT) | Real-Time PCR/Followed by Gel-Electrophoresis | 4 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | ||||||||
| AF1209 | Kappa And Lambda-Free Freelite | Nephelometry | 4 Days | hemaCORE | haematology | cancer | |||||||||
| IA1654 | CDK4 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1789 | FLI-1 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1261 | CD56 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1140 | ALK-1(CD246) | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1338 | BCL-2 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1131 | CD20 CY | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1133 | CD3 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1643 | CD99 (IHC) | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1670 | CD34 (IHC) | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1439 | CK5/6 | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1135 | LCA (CD45) | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| IA1899 | CD138 (diagnosis of multiple myeloma) | IHC | 4 Days | hemaCORE | oncology | ||||||||||
| MN1405 | Heme Multigene Panel | Next Generation Sequencing | 30 Days | hemaCORE | |||||||||||
| BB1708 | Osmotic Fragility Test; RBC Fragility Test | Spectrophotometry | 3 Days | hemaCORE | |||||||||||
| ME1005 | BCR-ABL Quant with p210 breakpoint | RT-PCR | 3 Days | hemaCORE | haematology | cancer | Philadelphia chromosome | chronic myelogenous leukemia | CML | ||||||
| ME1000 | BCR - Abl Qualitative (t (9;22)) | RT-PCR | 3 Days | hemaCORE | haematology | cancer | Philadelphia chromosome | chronic myelogenous leukemia | CML | ||||||
| ME1002 | BCR - Abl Quantitative- IS | RQ PCR | 3 Days | hemaCORE | haematology | cancer | Philadelphia chromosome | chronic myelogenous leukemia | CML | ||||||
| BH1051 | Hemoglobin Electrophoresis | HPLC | 3 Days | hemaCORE | |||||||||||
| WB1446 | MDS by Flow | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | Myelodysplastic | ||||||||
| WB1426 | Lymphocyte subset panel With NK cells (Percent and absolute count of CD3, CD4, CD8, CD 19, CD16/56) | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| WB1141 | CLL MRD | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | Chronic Lymphocytic Leukemia | ||||||||
| WB1215 | AML MRD | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | minimum | residual | ||||||
| WB1144 | Multiple Myeloma MRD | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| WB1447 | Flow Cytometry, Individual marker- CD 19 | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| WB1088 | ALL MRD | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | acute lymphoblastic leukemia | minimum | residual | ||||||
| WB1451 | Leukemia diag/MRD combo panel | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| AC1160 | Protein C, Functional | Chromogenic Assay | 3 Days | hemaCORE | |||||||||||
| AB1040 | Erythropoietin (EPO) | Chemiluminescence | 3 Days | hemaCORE | |||||||||||
| BH1142 | Multiple Myeloma comprehensive panel Qualitative | Agarose gel electrophoresis | 3 Days | hemaCORE | haematology | cancer | |||||||||
| ME1837 | Sarcoma Mutation Analysis Panel, Pediatric, PCR | Real-Time Polymerase Chain Reaction (RT-PCR) | 20 Days | hemaCORE | haematology | cancer | |||||||||
| ME1013 | PML Rara Quantitative | RT-PCR | 2 Days | hemaCORE | haematology | cancer | |||||||||
| ME1012 | PML Rara Qualitative | RT-PCR | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1422 | Flowcytometry - PNH Diagnostic Panel (CD33,CD45,CD55,CD59) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1196 | Multiple Myeloma (CD45,CD138,CD38,CD19,CD117,CD45,Cy Lambda,Cy Kappa,CD56) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1448 | ZAP70 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1197 | PNH Adv- CD(45, 15, 24, FLAER, 14, 64, 59,235a) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1181 | PNH Basic- CD(45, 15, 24, FLAER, 14, 64) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1261 | CD56 (Natural Killer Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1135 | CD45 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1131 | CD20 (B - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1139 | CD19 ( B-Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1134 | CD5 (T Cell / B - Cell Subset Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1130 | CD4 (Helper T - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1133 | CD3 (T - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1081 | CLPD/Leukemia | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | Chronic Lymphoproliferative Disorders | ||||||||
| WB1080 | CLPD Advance | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | Chronic Lymphoproliferative Disorders | ||||||||
| WB1079 | CLPD Basic | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | Chronic Lymphoproliferative Disorders | ||||||||
| WB1087 | Leukemia-Advance | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1086 | Leukemia-Basic | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1846 | CD23 (CLL Segregation Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| NA1704 | Myeloid Tumor panel | Next Generation Sequencing | 17 Days | hemaCORE | haematology | cancer | |||||||||
| P00021 | MPN Panel 3 (BCR/ABL Qualitative, JAK2 (12-15), MPL, CALR) | As mentioned in individual tests | 15 Days | hemaCORE | haematology | cancer | |||||||||
| MM1148 | IG VH Gene Mutation Detection | PCR Sequencing | 15 Days | hemaCORE | haematology | cancer | |||||||||
| P00073 | AML Multiplex-Advance (BCR - ABL, PML RaRa, AML ETO, INV 16, NPM1, FLT3,c-KIT,CEBPA) | PCR Sequencing | 15 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | ||||||||
| P00018 | MPN Panel 1 ((JAK-2 (12-15),MPL,CALR) | PCR Sequencing | 15 Days | hemaCORE | haematology | cancer | |||||||||
| MA1684 | B Cell Gene Rearrangements IGH Clonality | PCR | 15 Days | hemaCORE | |||||||||||
| ME1016 | NPM-1 | Mutation Analysis | 15 Days | hemaCORE | haematology | cancer | |||||||||
| ME1085 | CEBPA | Mutation Analysis | 15 Days | hemaCORE | haematology | cancer | |||||||||
| P00149 | MPN Panel 2 ((Jak-2 Exon 14-12 reflex testing, MPL) | Multiple Technologies | 15 Days | hemaCORE | haematology | cancer | |||||||||
| P00076 | Leukemia reflex panel-1 (Adv. to AML/ALL Multiplex basic, CEBPA) | As mentioned in individual tests | 15 Days | hemaCORE | haematology | cancer | |||||||||
| OA2070 | Fanconi Anemia DNA Mutation Analysis (FANCC gene targeted mutation analysis) | Allele-Specific Primer Extension • Fluorescent Detection Using Color Coded Microspheres • Polymerase Chain Reaction (PCR) | 15 Days | hemaCORE | haematology | cancer | |||||||||
| YB2115 | ALCL (Anaplastic large cell Lymphoma) t(2;5) | FISH | 13 Days | hemaCORE | |||||||||||
| P00004 | NPM-1,CEBPA,FLT3 | PCR Sequencing | 12 Days | hemaCORE | haematology | cancer | |||||||||
| NA1218 | HLA Typing- Advanced (A,B,C,DQ & DR, DPB1) | NGS (High Resolution) | 12 Days | hemaCORE | haematology | cancer | human leukocyte antigen | transplant | |||||||
| NA1020 | HLA Typing - Basic (A,B,DR) | NGS (High Resolution) | 12 Days | hemaCORE | haematology | cancer | human leukocyte antigen | transplant | |||||||
| P00024 | Leukemia reflex panel -2 (A.Lek.basic+Karyotype+AML/ALL Multiplex Basic | Multiple Technologies | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1275 | C-Myc gene rearrangement | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1316 | BCL6(3q27) translocation | FISH | 12 Days | hemaCORE | haematology | cancer | B-Cell Lymphoma | ||||||||
| YB1321 | BCL2(18q21.3)translocation | FISH | 12 Days | hemaCORE | haematology | cancer | B-Cell Lymphoma | ||||||||
| YB1461 | t(11;18)API2/MALT1 | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1189 | t(8;14) IGH/MYC | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1315 | t(14;18)IGH/BCL2 | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1203 | Synovial Sarcoma | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1606 | t(X;17) | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1127 | FGFR1(8p12) translocation | FISH | 12 Days | hemaCORE | haematology | cancer | fibroblast growth factor receptor | ||||||||
| YC1113 | Fanconi Anemia | Cytogenetics | 12 Days | hemaCORE | haematology | cancer | |||||||||
| P00047 | Double/Triple Hit Lymphoma (tissue) | As mentioned in individual tests | 12 Days | hemaCORE | |||||||||||
| MM1019 | MPL w515 | PCR-DNA Sequencing | 10 Days | hemaCORE | haematology | cancer | |||||||||
| MA1184 | Chimerism-Pre Engraftment, Donor & Recipient | PCR, Fragment analysis | 10 Days | hemaCORE | haematology | cancer | |||||||||
| MA1188 | Chimerism-Post Engraftment | PCR Fragment analysis | 10 Days | hemaCORE | haematology | cancer | |||||||||
| MM1029 | MTHFR | PCR Sequencing | 10 Days | hemaCORE | |||||||||||
| NA2236 | hemaCORE HLA high resolution (A,B,C,DR,DQ,DPB1) | Next Generation Sequencing | 10 Days | hemaCORE | |||||||||||
| NA2109 | hemaCORE HLA high resolution (A,B,C,DR,DQ) | Next Generation Sequencing | 10 Days | hemaCORE | |||||||||||
| MM1006 | c- KIT Mutation Analysis (GIST) | Mutation Analysis | 10 Days | hemaCORE | oncology | cKiT | gastric | ||||||||
| ME1008 | Jak 2 Exon 12 | Mutation Analysis | 10 Days | hemaCORE | haematology | cancer | |||||||||
| MP1007 | CALR | Mutation Analysis | 10 Days | hemaCORE | haematology | cancer | Calreticulin | calregulin | CRP55 | ||||||
| AK1650 | HTLV 1 And 2 virus | Enzyme immunoassay | 10 Days | hemaCORE | |||||||||||
| YC1050 | Karyotyping for Hematological Malignancies | Culture Karyotyping & Microscopy | 10 Days | hemaCORE | haematology | cancer | |||||||||
| GA1214 | Von Willebrand Antigen | Coagulation | 10 Days | hemaCORE | |||||||||||
| BV1059 | Multiple Myeloma comprehensive panel Quantitative Urine | Agarose gel electrophoresis & Immunofixation | 10 Days | hemaCORE | haematology | cancer | |||||||||
| BB1363 | C- Reactive Protein (CRP) | Spectrophotometry | 1 Day | hemaCORE | |||||||||||
| AK1325 | Beta 2 Glycoprotein 1 Panel (IgG, IgM, IgA) | Enzyme immunoassay | Sample By Sat/Wed, Report In 5 Days | gynaeCORE | |||||||||||
| YC1300 | Product of Conception (POC), Cytogenetics + reflex FISH | Karyotyping + Reflex FISH | 4 Weeks | gynaeCORE | gynaecology | ||||||||||
| OA1735 | BOH | Multiple Technologies | 4 Days | gynaeCORE | |||||||||||
| ME1639 | Chlamydia Trachomatis And Neisseria Gonorrhoeae | RT-PCR | 3 Days | gynaeCORE | |||||||||||
| BD1713 | Endomysial Antibody IgA | Immunofluorescence Assay | 3 Days | gynaeCORE | |||||||||||
| AB1615 | Inhibin A, Reproductive Marker | CMIA | 3 Days | gynaeCORE | |||||||||||
| AB1043 | Anti Mullerian Hormone (AMH) | CLIA | 3 Days | gynaeCORE | |||||||||||
| AB1544 | Torch Panel IgG & IgM | Chemiliminescent Immunoassay | 3 Days | gynaeCORE | |||||||||||
| AB1115 | Maternal Serum Screen 3; Triple Test | Chemiliminescent Immunoassay | 2 Days | gynaeCORE | |||||||||||
| AB1066 | Maternal Serum Screen 2; Dual Test | Chemiliminescent Immunoassay | 2 Days | gynaeCORE | |||||||||||
| AB1047 | Maternal Serum Screen 4; Quadruple Test | Chemiliminescent Immunoassay | 2 Days | gynaeCORE | |||||||||||
| YC1111 | Cytogenetics (Couple Karyotyping) | Karyotyping | 12 Days | gynaeCORE | karyotype | ||||||||||
| YC1112 | Cytogenetics (Genetic Disorders) | Karyotyping | 12 Days | gynaeCORE | karyotype | ||||||||||
| MI1207 | Y Chromosome Microdeletion Analysis 16 STS Markers (only for males) | Multiplex PCR | 10 Days | gynaeCORE | |||||||||||
| OA1829 | Coeliac Comprehensive profile | Multiple Technologies | Sample By Sat, Tue. Report In 3 Days | gastriCORE | |||||||||||
| MN1129 | Hepatitis B Viral Drug Resistance & Genotyping | PCR-Sequencing | 8 Days | gastriCORE | |||||||||||
| P00012 | HCV RNA Quantitative & Genotype | Real-Time PCR | 5 Days | gastriCORE | |||||||||||
| P00058 | HCV RNA Quantitative & Genotype (Reflex panel) | Real time PCR | 5 Days | gastriCORE | |||||||||||
| SA1813 | Comprehensive Food Intolerance Panel | Protein Microarray | 5 Days | gastriCORE | |||||||||||
| AB1357 | Fecal Calprotectin | CLIA | 5 Days | gastriCORE | |||||||||||
| ME1035 | HCV Genotyping (Genotype 1,2,3.4,5,6) | Real-Time RT PCR | 3 Days | gastriCORE | |||||||||||
| ML1033 | HCV RNA Qualitative | Real Time PCR- Rotor Gene Q | 3 Days | gastriCORE | |||||||||||
| MA1150 | HBV DNA Qualitative | Real Time PCR- Rotor Gene Q | 3 Days | gastriCORE | |||||||||||
| AH1281 | Hepatitis C Virus (Anti HCV) | ELISA | 3 Days | gastriCORE | |||||||||||
| A11238 | Hepatitis E Antibody (Anti-HEV), IgM | ELISA | 3 Days | gastriCORE | haematology | cancer | |||||||||
| ML1034 | HCV RNA Quantitative | Real Time PCR- Rotor Gene Q | 2 Days | gastriCORE | |||||||||||
| ML1032 | HBV DNA Quantitative | Real Time PCR- Rotor Gene Q | 2 Days | gastriCORE | |||||||||||
| MA2186 | Hepatitis A Virus RNA Detection | PCR | 10 Days | gastriCORE | |||||||||||
| P00124 | HCV & HBsAg Rapid Qualitative | Rapid card method | 1 Day | gastriCORE | |||||||||||
| B51720 | HCV Rapid Qualitative | Immuno Chromatography | 1 Day | gastriCORE | |||||||||||
| AO1281 | HEPATITIS C VIRUS (Anti-HCV) | Chemiluminescent Microparticle Immunoassay | 1 Day | gastriCORE | |||||||||||
| WB1900 | HPV E6/E7 | Flow Cytometry | 6 Days | cerviCORE | |||||||||||
| PA1696 | LBC + HPV high risk (hybrid capture) | hybrid capture | 5 Days | cerviCORE | liquid | papilloma | sexual | reproductive | gynaecology | ||||||
| MA1052 | HPV (HUMAN PAPILLOMA VIRUS) Detection & Genotyping, Qualitative | Real Time PCR | 4 Days | cerviCORE | papilloma | reproductive | gynaecology | ||||||||
| ME1283 | HPV DNA | RT-PCR | 3 Days | cerviCORE | papilloma | reproductive | gynaecology | ||||||||
| P00066 | Reflex testing (HPV +ve to LBC) | Real Time PCR | 3 Days | cerviCORE | gynaecology | ||||||||||
| P00049 | Reflex testing (LBC +ve to HPV DNA) | Real Time PCR | 3 Days | cerviCORE | gynaecology | ||||||||||
| CA1053 | LBC ( Liquid Based Cytology) | Cytology | 3 Days | cerviCORE | liquid | reproductive | gynaecology | ||||||||
| P00007 | LBC + HPV DNA (RT-PCR) | As mentioned in individual tests | 3 Days | cerviCORE | liquid | papilloma | sexual | reproductive | gynaecology | ||||||
| AH1240 | Inhibin B | Enzyme immunoassay | Sample By Saturday, Report In 3 Days | onCORE | |||||||||||
| OA2128 | Cancer Targeted Gene Panel Colon/Colorectal | IHC,NGS | Sample By Mon, Report In 12 Days | onCORE | |||||||||||
| MA1563 | COREprime EGFR | PCR | Next Day (Cut Off 12 Noon) | onCORE | oncology | lung | |||||||||
| IA1610 | COREprime ROS1 | Immunohistochemistry | Next Day (Cut Off 12 Noon) | onCORE | |||||||||||
| IA1609 | COREprime ALK | Immunohistochemistry | Next Day (Cut Off 12 Noon) | onCORE | |||||||||||
| P00100 | COREprime Lung Panel 2 (EGFR (PCR)+ALK(IHC)+ROS1(IHC)) | As mentioned in individual tests | Next Day (Cut Off 12 Noon) | onCORE | |||||||||||
| P00099 | COREprime Lung Panel 1 (ALK+EGFR) | As mentioned in individual tests | Next Day (Cut Off 12 Noon) | onCORE | |||||||||||
| IA1682 | VEGF IHC | IHC | Ffpe Bloack-4 Days Small Biopsy- 4 Days Medium Biospy- 5 Days Large Biopsy- 6 Days Radical- 7 Days | onCORE | |||||||||||
| IA1076 | Her2neu | IHC | Ffpe Bloack-4 Days Small Biopsy- 4 Days Medium Biospy- 5 Days Large Biopsy- 6 Days Radical- 7 Days | onCORE | oncology | breast | mamma | herceptin | |||||||
| IA1147 | Progesterone Receptor | IHC | Ffpe Bloack-4 Days Small Biopsy- 4 Days Medium Biospy- 5 Days Large Biopsy- 6 Days Radical- 7 Days | onCORE | oncology | ||||||||||
| IA1149 | Estrogen Receptor (ER) | IHC | Ffpe Bloack-4 Days Small Biopsy- 4 Days Medium Biospy- 5 Days Large Biopsy- 6 Days Radical- 7 Days | onCORE | oncology | breast | mamma | ||||||||
| NA1816 | geneCORE Paradigm Immunotherapy Panel (TMB + PD-L1 IHC) + MSI | Next Generation Sequencing | Block-10 Days Tissue-12 Days | onCORE | |||||||||||
| NA1571 | geneCORE Paradigm Tumor Mutational Burden (TMB) stand alone + MSI | Next Generation Sequencing | Block-10 Days Tissue-12 Days | onCORE | |||||||||||
| NA1410 | Paradigm NGS (DNA+TMB) as well as primary(7-13) IHC panel + MSI | NGS+ IHC | Block- 10 Days Tissue - 12 Days | onCORE | oncology | ||||||||||
| NA1411 | Paradigm NGS (DNA+TMB) + MSI | Next Generation Sequencing | Block- 10 Days Tissue - 12 Days | onCORE | oncology | ||||||||||
| NA1092 | Paradigm NGS (DNA+TMB) as well as primary(14-24) IHC panel + MSI | Next Generation Sequencing | Block- 10 Days Tissue - 12 Days | onCORE | oncology | foundation | wgs | wes | |||||||
| P00051 | c-Kit, PDGFRA (Mutation Analysis) | Mutation Analysis | As Mentioned In Individual Tests | onCORE | oncology | gastric | |||||||||
| P00027 | EGFR +ALK (FISH)+ROS-1+MET, HER2(FISH), PDL-1 | As mentioned in individual tests | As Mentioned In Individual Tests | onCORE | oncology | lung | pulmo | ||||||||
| P00020 | EGFR (mutation analysis)+ALK Protein (lung) IHC +ROS-1 | As mentioned in individual tests | As Mentioned In Individual Tests | onCORE | oncology | lung | pulmo | ||||||||
| P00079 | EGFR Mutation Analysis + ALK (FISH) + ROS1 (FISH) + PDL1 (IHC) + BRAF Mutation Analysis | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | |||||||||||
| P00105 | EGFR Mutation Analysis + ALK (FISH) + ROS1 (FISH) + PDL1 (IHC) | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | |||||||||||
| P00116 | EGFR Mutation Analysis + ALK (IHC)+ ROS1 (FISH) + PDL1 (IHC) | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | |||||||||||
| P00015 | EGFR (mutation analysis)+ALK Protein (lung) IHC | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | oncology | lung | pulmo | ||||||||
| P00013 | EGFR (mutation analysis)+ALK FISH | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | oncology | lung | pulmo | ||||||||
| P00019 | EGFR (mutation analysis) +ALK FISH +ROS-1 | As mentioned in individual tests | As Mentioned For Individual Tests | onCORE | oncology | lung | pulmo | ||||||||
| ME1069 | NRAS Mutation Analysis | Real Time-PCR | 8 Days | onCORE | oncology | ||||||||||
| MM1336 | PDGFRA Mutation Analysis-Solid Tumors | PCR followed by Sequencing | 8 Days | onCORE | oncology | ||||||||||
| MM1101 | IDH 1 &2 | Mutation Analysis | 8 Days | onCORE | brain | ||||||||||
| MM1017 | TPMT Genotyping | Mutation Analysis | 8 Days | onCORE | haematology | cancer | |||||||||
| YB1078 | ALK Fusion | FISH | 8 Days | onCORE | oncology | lung | pulmo | ||||||||
| MB1109 | liquiCORE CTC (lung Cancer) | Proprietary Platform | 8 Days | onCORE | oncology | liquid | ctc | lung | monitoring | ||||||
| MB1386 | liquiCORE CTC (Prostate Cancer) | Proprietary Platform | 8 Days | onCORE | oncology | liquid | ctc | prostrate | monitoring | ||||||
| MB1049 | liquiCORE CTC (Breast Cancer) | Proprietary Platform | 8 Days | onCORE | oncology | liquid | ctc | breast | monitoring | ||||||
| P00061 | EGFR (mutation analysis) +ALK IHC+ROS1 FISH+MET FISH | As mentioned in individual tests | 8 Days | onCORE | oncology | lung | pulmo | ||||||||
| P00026 | EGFR (mutation analysis) +ALK FISH+ROS1 FISH+MET FISH | As mentioned in individual tests | 8 Days | onCORE | oncology | lung | pulmo | ||||||||
| P00101 | COREprime Lung Panel 3 (EGFR (PCR)+ALK(IHC)+ROS1(IHC) reflex to ROS1(FISH)) | As mentioned in individual tests | 8 Days | onCORE | |||||||||||
| NA1299 | uniCORE | Next Generation Sequencing | 7 Weeks | onCORE | oncology | cellworks | personalize | ||||||||
| AK1039 | Chromogranin A Serum | RadioImmunoassay | 7 Days | onCORE | |||||||||||
| YB1104 | 1p19q | FISH | 7 Days | onCORE | brain | ||||||||||
| YB1121 | PDGFRB (5q33) translocation | FISH | 7 Days | onCORE | haematology | cancer | |||||||||
| YB1270 | 17p deletion | FISH | 7 Days | onCORE | haematology | cancer | Chronic Lymphocytic Leukemia | CLL | |||||||
| P00006 | KRAS, NRAS, BRAF Mutation Analysis | As mentioned in individual tests | 7 Days | onCORE | oncology | colon | |||||||||
| MM1119 | Microsatellite Instability | PCR Sequencing | 6 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| IA1302 | Any 7 IHC markers with interpretation | IHC | 6 Days | onCORE | oncology | ||||||||||
| IA1055 | dualCORE (Unlimited Markers) | IHC | 6 Days | onCORE | oncology | final diagnosis | diagnosis | second opinion | |||||||
| IA1083 | dualCORE (Upto 7 Markers) | IHC | 6 Days | onCORE | oncology | final diagnosis | diagnosis | second opinion | |||||||
| YB1060 | EGFR | FISH | 6 Days | onCORE | oncology | lung | pulmo | ||||||||
| YB1071 | ROS-1 | FISH | 6 Days | onCORE | oncology | lung | |||||||||
| YB1290 | MET | FISH | 6 Days | onCORE | oncology | lung | pulmo | ||||||||
| MG1619 | EGFR T790 Mutation analysis | ddPCR | 6 Days | onCORE | oncology | lung | pulmo | ||||||||
| NA1295 | PulmoCORE Comprehensive (without PDL1 on Blood) | Next Generation Sequencing | 5 Weeks | onCORE | oncology | lung | |||||||||
| NA2037 | pulmoCORE Comprehensive panel (blood) | Next Generation Sequencing | 5 Weeks | onCORE | oncology | lung | |||||||||
| NA1296 | liquiCORE Detect | Next Generation Sequencing | 5 Weeks | onCORE | oncology | liquid | |||||||||
| ME1068 | KRAS Mutation Analysis | Real Time-PCR | 5 Days | onCORE | oncology | colon | |||||||||
| MK1060 | EGFR Mutation Analysis | REAL TIME POLYMERASE CHAIN REACTION-ARMS PCR | 5 Days | onCORE | oncology | lung | pulmo | ||||||||
| IA1838 | PDL-1 22C3 Dako | Immunohistochemistry | 5 Days | onCORE | |||||||||||
| YB1076 | HER-2 FISH | FISH | 5 Days | onCORE | oncology | breast | mamma | herceptin | |||||||
| MG1114 | liquiCORE EGFR (cell free DNA) | Droplet Digital PCR | 5 Days | onCORE | oncology | liquid | |||||||||
| P00011 | ER/PR by IHC & Her2 neu FISH | As mentioned in individual tests | 5 Days | onCORE | oncology | breast | mamma | estrogen | progesterone | ||||||
| P00005 | KRAS and NRAS Mutation Analysis | As mentioned in individual tests | 5 Days | onCORE | oncology | colon | |||||||||
| NA1096 | geneCORE-Hotspot | Next Generation Sequencing | 4 Weeks | onCORE | oncology | ||||||||||
| NA2177 | geneCORE Homologous Recombination Deficiency | Next Generation Sequencing | 4 Weeks | onCORE | |||||||||||
| NA1146 | geneCORE Predict | Next Generation Sequencing | 4 Weeks | onCORE | oncology | screening | prevention | ||||||||
| MC1276 | mammaCORE BRCA 1 &2 deletion duplication panel | MLPA | 4 Weeks | onCORE | oncology | brca1 | breast | brca | |||||||
| IA1666 | PAX-8 (diagnosis of follicular, thyroid, renal carcinoma) | IHC | 4 Days | onCORE | endocrine | endocrinology | |||||||||
| IA2120 | VENTANA ANTI-ALK (D5F3) Rabbit Monoclonal | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1071 | ROS1 (D4D6 R) Rabbit Mab CST | Immunohistochemistry | 4 Days | onCORE | oncology | lung | |||||||||
| IA1653 | NKX3.1 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1395 | ATRX | IHC | 4 Days | onCORE | oncology | brain | neuro | ||||||||
| IA1440 | E-Cadherin | IHC | 4 Days | onCORE | oncology | lung | pulmo | ||||||||
| IA1090 | VENTANA PDL-1 (SP263) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1339 | CMYC Ep121 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1103 | Anti -IDH1 R132H (Hu) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1193 | Androgen Receptor | IHC | 4 Days | onCORE | oncology | breast | |||||||||
| IA1661 | GATA-3 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1383 | Any 7 IHC markers with diagnosis | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1095 | Any 5 IHC markers with diagnosis | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1220 | Any 3 IHC markers with diagnosis | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1221 | Any 2 IHC markers with diagnosis | IHC | 4 Days | onCORE | oncology | ||||||||||
| P00009 | ER,PR,HER2neu,Ki67 | IHC | 4 Days | onCORE | oncology | breast | mamma | estrogen | progesterone | ||||||
| IA1097 | ALK protein (Lung) | IHC | 4 Days | onCORE | oncology | lung | pulmo | ||||||||
| P00062 | Ki67,p53,ER/PR, Her2neu | IHC | 4 Days | onCORE | oncology | breast | mamma | herceptin | |||||||
| IA1665 | p40 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1782 | Napsin A | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1887 | p16 (diagnosis of head & neck cancer) | IHC | 4 Days | onCORE | oncology | brain | head | ||||||||
| IA1105 | Any 2 IHC markers with interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1106 | Any 5 IHC markers with interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1107 | Any 3 markers with interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1054 | MMR panel | IHC | 4 Days | onCORE | oncology | colon | immunotherapy | ||||||||
| P00008 | ER,PR, Her2neu | IHC | 4 Days | onCORE | oncology | breast | mamma | estrogen | progesterone | ||||||
| IA1425 | AMACR | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1060 | EGFR(IHC) | IHC | 4 Days | onCORE | oncology | lung | pulmo | ||||||||
| IA1640 | p63 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1432 | CK19 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1797 | CDX2 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1006 | CD117 (c-KIT) | IHC | 4 Days | onCORE | oncology | ||||||||||
| P00010 | ER,PR combined | IHC | 4 Days | onCORE | oncology | breast | mamma | estrogen | progesterone | ||||||
| IA1337 | TTF 1 | IHC | 4 Days | onCORE | endocrine | endocrinology | |||||||||
| IA1223 | P53 PROTEIN | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1605 | PMS2 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1604 | MSH6 DBS | IHC | 4 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| IA1396 | MSH2 | IHC | 4 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| IA1354 | MLH1 | IHC | 4 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| IA1077 | Ki-67 with Interpretation | IHC | 4 Days | onCORE | oncology | breast | mamma | ||||||||
| IA1672 | Cytokeratin (Pancytokeratin) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1430 | Chromogranin A | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1431 | S100 | IHC | 4 Days | onCORE | oncology | ||||||||||
| NA1408 | GeneCORE Comprehensive Tumor Panel (73 genes) | Next Generation Sequencing | 35 Days | onCORE | oncology | ||||||||||
| NA1403 | geneCORE Deep Gene Sequencing | Next Generation Sequencing | 30 Days | onCORE | oncology | ||||||||||
| NA1407 | Somatic mutation analysis of BRCA 1 & 2 | Next Generation Sequencing | 30 Days | onCORE | oncology | ||||||||||
| NA1414 | TERT mutation - full gene sequencing | Next Generation Sequencing | 30 Days | onCORE | oncology | brain | neuro | ||||||||
| NA1031 | mammaCORE BRCA Comprehensive test | MLPA & NGS | 30 Days | onCORE | oncology | brca1 | breast | brca | |||||||
| AB1729 | Tumour Necrosis Factor (TNF) ,Alpha | Chemiliminescent Immunoassay | 3 Days | onCORE | |||||||||||
| NA1504 | PulmoCORE panel 3 | Next Generation Sequencing | 23 Days | onCORE | |||||||||||
| NA1706 | GlioSeq | Next Generation Sequencing | 21 Days | onCORE | |||||||||||
| MN1354 | MLH1 Mutation Analysis | Sequencing | 20 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| MA2093 | RAS Mutation Analysis, Cell-based (HRAS Mutation KRAS Mutation NRAS Mutation) (Colon Cancer) | Polymerase Chain Reaction (PCR) • Sequencing | 20 Days | onCORE | oncology | colon | |||||||||
| NA1152 | Mammaprint +Blueprint | Next Generation Sequencing | 20 Days | onCORE | |||||||||||
| NA2011 | pulmoCORE PDL1 (Blood) | Next Generation Sequencing | 2 Weeks | onCORE | oncology | lung | |||||||||
| WB1083 | Any 7 Markers | Flow Cytometry | 2 Days | onCORE | haematology | cancer | |||||||||
| WB1778 | Any 5 Markers | Flow Cytometry | 2 Days | onCORE | haematology | cancer | |||||||||
| MT1991 | MLH1 Hypermethylation | Pyrosequencing | 18 Days | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| NA1443 | geneCORE Oncomine 52 gene panel | Next Generation Sequencing | 18 Days | onCORE | |||||||||||
| TS817 | PD-1 with Interpretation | IHC | 18 Days | onCORE | oncology | immunotherapy | |||||||||
| ME1903 | BRAF mutation analysis papillary thyroid cancer | Real Time PCR | 15 Days | onCORE | oncology | colon | |||||||||
| MW1659 | RET/PTC Rearrangement, thyroid cancer | Real Time PCR | 15 Days | onCORE | oncology | thyroid | |||||||||
| MA1392 | IDH 1 & 2 mutation (AML Patient only) | PCR | 15 Days | onCORE | haematology | cancer | neuroCORE | ||||||||
| P00117 | pulmoCORE 5 Gene Panel EGFR, BRAF, c-MET, ALK & ROS1 + Met Amplification | NGS, FISH | 15 Days | onCORE | |||||||||||
| NA1154 | Oncotype Dx | Next Generation Sequencing | 15 Days | onCORE | |||||||||||
| NA1030 | mammaCORE BRCA 1 &2 full gene sequencing | Next Generation Sequencing | 15 Days | onCORE | oncology | brca1 | breast | brca | |||||||
| MO1153 | mammaCORE Prosigna | nCounterDx | 15 Days | onCORE | oncology | breast | recurrence | ||||||||
| P00067 | Melanoma Panel I- CKIT & BRAF | Mutation Analysis | 15 Days | onCORE | oncology | ||||||||||
| MM1200 | UGT1A1 Genotyping | Mutation Analysis | 15 Days | onCORE | haematology | cancer | |||||||||
| P00141 | PulmoCORE Extended panel | Multiple Technologies | 15 Days | onCORE | |||||||||||
| AK1682 | Vascular Endothelial Growth Factor (VEGF) | Enzyme immunoassay | 15 Days | onCORE | |||||||||||
| MV2083 | Mutation Specific Testing | Sangers Sequencing | 14 Days | onCORE | oncology | ||||||||||
| NA1616 | Next Generation Sequencing | 7 Days + Logistics Time | onCORE | ||||||||||||
| ME1070 | BRAF | Mutation Analysis | 10 Days | onCORE | oncology | colon | |||||||||
| MM1201 | PI3K Pathway:(Mutation analysis) | Mutation Analysis | 10 Days | onCORE | oncology | ||||||||||
| ME1102 | MGMT | Methylation Specific PCR | 10 Days | onCORE | brain | ||||||||||
| IA1779 | Paradigm - PDL1 | IHC | 10 Days | onCORE | oncology | immunotherapy | |||||||||
| YB1833 | UroVysion | FISH | 10 Days | onCORE | |||||||||||
| AK1724 | Phospholipase A2 Receptor Antibody - Quantitative | Enzyme immunoassay | 10 Days | onCORE | |||||||||||
| P00064 | Glioma panel 1 (IDH (IHC) + ATRX (IHC) + IDH Mutation Analysis + MGMT + 1p19q) | As mentioned in individual tests | 10 Days | onCORE | brain | ||||||||||
| P00098 | Pulmo DDX (IHC), EGFR Mutation Analysis (Realtime-PCR), ALK (FISH) | As mentioned in individual tests | As Mentioned In Individual Tests | onCORE | oncology | lung | |||||||||
| TS606 | EGFR +ALK (FISH)+ROS-1+MET+HER2(FISH)+PDL-1+BRAF | As mentioned in individual tests | As Mentioned In Individual Test | onCORE | oncology | lung | pulmo | ||||||||
| MN1937 | MSH6 Gene Sequencing | Sequencing | 8 Weeks | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| MV1396 | MSH2 gene sequencing | Sangers Sequencing | 8 Weeks | onCORE | oncology | mmr | colon | immunotherapy | |||||||
| NA1397 | PMS2 gene sequencing | Next Generation Sequencing | 8 Weeks | onCORE | oncology | ||||||||||
| IA1942 | RCC | IHC | 8 Days | onCORE | oncology | renal | |||||||||
| MB1294 | liquiCORE CTC (Colorectal Cancer) | Proprietary Platform | 8 Days | onCORE | oncology | liquid | ctc | colon | colorectal | monitoring | |||||
| MB1981 | liquiCORE CTC (Pancreatic Cancer) | Proprietary Platform | 8 Days | onCORE | oncology | liquid | ctc | pancreatic | pancreas | monitoring | |||||
| IA2051 | TFE3 | IHC | 7 Days | onCORE | oncology | ||||||||||
| IA1424 | Immunohistochemistry, Individual Marker, Growth Hormone | IHC | 7 Days | onCORE | oncology | ||||||||||
| NA1996 | Hyperoxaluria (Next Generation Sequencing of AGXT, GRHPR, or HOGA1) | Next Generation Sequencing | 6 Weeks | onCORE | oncology | ||||||||||
| P00189 | Egfr Prime, Alk (ihc), Ros1(fish) | As mentioned in individual tests | 6 Days | onCORE | oncology | lung | pulmo | ||||||||
| HA1057RT | Biopsy,complex/radical | Histopathology | 6 Days | onCORE | oncology | ||||||||||
| NA1295TE | PulmoCORE Comprehensive (without PDL1 on Tissue) | Next Generation Sequencing | 5 Weeks | onCORE | oncology | lung | |||||||||
| IA2062 | Cytokeratin 8 | IHC | 5 Days | onCORE | oncology | ||||||||||
| HA1057LT | Histopathology, Biopsy, Large | Histopathology | 5 Days | onCORE | oncology | ||||||||||
| NA1406 | Marfan syndrome panel | Next Generation Sequencing | 4 Weeks | onCORE | oncology | ||||||||||
| MN1681 | X-linked dyserythropoietic anemia and thrombocytopenia GATA1 hotspot | Sequencing | 4 Weeks | onCORE | oncology | ||||||||||
| TS828 | BCL6 (BIOSB BSB-5079) | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| TS826 | GCDFP15 (EP95 Rabbit Monoclonal) | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| TS825 | Alpha Actin Smooth Muscle (EP188 Rabbit Monoclonal) SMA | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| TS823 | RABBIT MONOCLONAL NEGATIVE CONTROL Ig (HCL-1003) | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| TS822 | CD79A (Dako) | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1795 | Arginase 1 | IHC | 4 Days | onCORE | oncology | ||||||||||
| TS813 | Any 2 IHC markers without interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| TS807 | Any 7 IHC markers without interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1530 | Any 5 IHC markers without interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1909 | Any 3 IHC markers without interpretation | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1796 | Ber- Ep4 (EpCAM) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1786 | CD68 (diagnosis of malignant histiocytosis) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1884 | Uroplakin II | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1656 | D-240 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1894 | Calponin | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1791 | Beta catenin (EP35 Rabbit Monoclonal) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1798 | MPO (Is 51130-2) Dako | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1847 | CALDESMON | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1881 | TdT | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1657 | CD23 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1848 | SALL4 | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1849 | CD20 CY (Dako) | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1851 | Tinto MDM2 Predilute | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1890 | Tinto STAT6 RMab | IHC | 4 Days | onCORE | oncology | ||||||||||
| TS724 | Anti Vascular Endothelial Growth Factor (MA512184) VG1 | Immunohistochemistry | 4 Days | onCORE | oncology | ||||||||||
| IA1800 | CD7 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1902 | Glypican 3 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1860 | ERG-EP111-Rabbit Monoclonal | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1787 | PAX2-EP235-Rabbit Monoclonal) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1865 | INI1 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1879 | PSMA | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1867 | IHCL-0572 (LAMBDA Light Chain) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1889 | Annexin-A1 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1226 | MERTK | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1225 | CD44 TINTO | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1224 | OLIG22RMab | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1868 | Mammaglobin (diagnosis of primary & metastatic breast cancer) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1138 | CD21 (diagnosis of lymphomas) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1863 | HCG (diagnosis of chorio carcinoma) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1230 | Inhibin A (Diagnosis of granulosa cell ovarian Tumor) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1856 | CD43 (T cell Lymphoma) | IHC | 4 Days | onCORE | oncology | ||||||||||
| HA1057MT | Histopathology, Biopsy, Medium Specimen | Histopathology | 4 Days | onCORE | oncology | ||||||||||
| IA1187 | Kappa (Diagnosis of B-cell lymphomas) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1222 | Pulmo DDX | IHC | 4 Days | onCORE | oncology | lung | |||||||||
| IA1667 | HMWCK (Dako) | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1855 | CD31 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1792 | MELAN A | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1130 | CD4 (EP204) Rabbit Monoclonal | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1893 | Cyclin D1 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1895 | CD79A | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1875 | Neurofilament | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1871 | MUC2 | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1872 | MUC5AC- PM233-6ML | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1436 | GFAP | IHC | 4 Days | onCORE | oncology | ||||||||||
| IA1876 | OCT3/4 | IHC | 4 Days | onCORE | oncology | ||||||||||
| MN1400 | ESR1 gene Full gene sequencing | Sequencing | 30 Days | onCORE | oncology | breast | mamma | ||||||||
| MV1908 | Estrogen Resistance (ESR1 gene) (Carrier testing) | Sangers Sequencing | 30 Days | onCORE | oncology | breast | mamma | ||||||||
| NA1409 | Watson Genomics | Next Generation Sequencing/Illumina NextSeq | 30 Days | onCORE | oncology | IBM | watson | ||||||||
| IA1870 | MUC 1 | IHC | 3 Days | onCORE | oncology | ||||||||||
| IA1911 | IHC without Interpretation | IHC | 3 Days | onCORE | oncology | ||||||||||
| MC1954 | VHL gene deletion/duplication | MLPA | 28 Days | onCORE | oncology | ||||||||||
| MV1955 | VHL gene mutation 3 exons by sequencing | Sangers Sequencing | 28 Days | onCORE | oncology | ||||||||||
| HB931 | liquiCORE BRAF | Next Generation Sequencing | 25 Days | onCORE | oncology | colon | liquid | monitoring | |||||||
| MT1332 | RAS Mutation Analysis, Thyroid cancer (codons 12, 13 and 61 of HRAS, KRAS and NRAS) | Pyrosequencing | 20 Days | onCORE | oncology | lung | |||||||||
| TS782 | Slide/ Block return (upto 10 blocks) | IHC | 2 Days | onCORE | oncology | ||||||||||
| TS725 | Histo Biopsy Frozen section | Histology | 2 Days | onCORE | oncology | ||||||||||
| TS639 | Tissue Block return- upto 5 blocks | IHC | 2 Days | onCORE | oncology | ||||||||||
| TS638 | Tissue Block return- upto 4 blocks | IHC | 2 Days | onCORE | oncology | ||||||||||
| TS637 | Tissue Block return- upto 3 blocks | IHC | 2 Days | onCORE | oncology | ||||||||||
| NA1629 | geneCORE Me | Next Generation Sequencing | 18 Days | onCORE | oncology | ||||||||||
| MA2000 | Sickle Cell Mutation Detection | PCR | 18 Days | onCORE | oncology | ||||||||||
| HB1215 | 22q11 microdeletion (DiGeorge syndrome) | MLPA | 15 Days | onCORE | oncology | ||||||||||
| MN1982 | TERT mutation Carrier testing | Sequencing | 15 Days | onCORE | oncology | brain | neuro | ||||||||
| TS851 | Serum Associated Amyloid IHC marker (SAA) | IHC | 10 Days | onCORE | oncology | ||||||||||
| P00147 | Melanoma Panel II- CKIT, BRAF & NRAS | Mutation Analysis | 10 Days | onCORE | oncology | ||||||||||
| IA2012 | Paradigm - PD1 | IHC | 10 Days | onCORE | oncology | immunotherapy | |||||||||
| MV2056 | Marfan Syndome, Carrier testing | Sangers Sequencing | 10 Days | onCORE | oncology | ||||||||||
| HB1142 | Bacterial Meningitis Panel (H. Influenzae, N. Meningitis, S.Pnemoniae | Multiplex PCR | Sample Wed/Sat, Report In 2 Days | neuroCORE | brain | ||||||||||
| HB1136 | Freidrichs Ataxia Mutation Panel | PCR-RFLP | Sample Mon/Wed/Sat Report In 10 Days | neuroCORE | brain | ||||||||||
| HB1137 | Rett Syndrome | PCR Sequencing | Sample Mon/Thu, Report 10 Days | neuroCORE | brain | ||||||||||
| HB1138 | Angelmans Syndrome | MS-PCR | Sample By Sat, Report 10 Days | neuroCORE | brain | ||||||||||
| MA1998 | Spino Cerebral Ataxia -SCA Panel (1,2,3,6,7,12) | PCR | Sample By Mon, Report In 8 Days | neuroCORE | brain | ||||||||||
| HB1151 | Multiple Sclerosis Panel- Basic (Albumin-CSF & Serum, IgG-CSF & Serum, Oligoclonal Band, CSF Index) | Multiple Technologies | Sample By Mon, Report 3 Days | neuroCORE | brain | ||||||||||
| P00093 | Glioma panel 2 (Neuro DDX(IHC), MGMT(MS PCR), IDH 1 & 2 (Mutation Analysis), 1p19q (FISH)) | As mentioned in individual tests | As Mentioned In Individual Tests | neuroCORE | brain | ||||||||||
| MC1984 | Spinal muscular atrophy ( SMA ) | MLPA | 9 Days | neuroCORE | brain | ||||||||||
| HB1268 | Rett syndrome ( MECP2 sequencing and Deletion / duplication ) | NGA+MLPA | 7 Weeks | neuroCORE | brain | ||||||||||
| YB1380 | 1p deletion | FISH | 7 Days | neuroCORE | brain | ||||||||||
| IA1583 | NeuroDDX | IHC | 7 Days | neuroCORE | brain | ||||||||||
| HB1143 | Duchenne Muscular Dystrophy (DMD)/BMD deletion/duplication analysis | a CGH | 6-8 Weeks | neuroCORE | brain | ||||||||||
| HB1280 | Dystonia ( DYT5 gene sequencing ) | Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1279 | Dystonia (DYT1 gene sequencing) | Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1267 | Rett syndrome MECP2 Sequencing | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1130 | Hereditary Neuropathies Panel | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1129 | Epilepsy and Seizure Disorders | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1128 | Ataxia-Telangiectesia Panel | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1127 | Autism Spectrum Disorder | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1125 | Parkinson's Disease Panel | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1124 | Dystonia Panel | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1122 | Peroxisomal Disorders | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1120 | Lysosomal Storage Disorders- Tay Sachs Disease(HEXA) | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1119 | Limb Girdle Muscular Dystrophy | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1118 | Joubert syndrome | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1117 | Duchenne Muscular Dystrophy (Next Generation Sequencing of full dystrophin / DMD gene) | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| HB1116 | Congenital Muscular Dystrophy | Next Generation Sequencing | 5 Weeks | neuroCORE | brain | ||||||||||
| MA1820 | Friedreich ataxia - molecular diagnosis | Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| NA2036 | Angelman syndrome methylation test | Next Generation Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| NA1941 | Prader Willi syndrome (PWS) | Next Generation Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1287 | Spinal cerebellar ataxia package ( 1, 2, 3, 6, 7, 12, 17 ) | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1286 | Spinal cerebellar ataxia package ( 1, 2, 3, 12 ) | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1284 | Spinal muscular atrophy -SMN2 copy number analysis | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1283 | Spinal Muscular Atrophy - SMN 1 Gene Sequencing | Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1281 | Spinal muscular atrophy ( SMA ) - molecular diagnosis | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1273 | Thrombophilia profile (DNA)-3 polymorphisms | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1272 | Wilsons Disease- 5 common mutations | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1271 | Wilson linkage presymptomatic | Multiplex PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1270 | LGMD2E common mutations (exons 19 & 22) | Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1266 | RETT Syndrome MECP2 Deletion/Duplication | MLPA | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1265 | Rett syndrome atypical -CDKL5 MLPA | MLPA | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1264 | Fragile X syndrome (Methylation) | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1263 | Fragile X in Females | PCR | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1262 | Fragile X- FMR1/AFF2 probemix MLPA | MLPA | 4 Weeks | neuroCORE | brain | ||||||||||
| HB1259 | Sequencing Parkinson ( Gly19 ser mutation ) | Sequencing | 4 Weeks | neuroCORE | brain | ||||||||||
| MQ1208 | Fragile X chromosome analysis | PCR, Capillary Eletrophoresis | 4 Weeks | neuroCORE | brain | ||||||||||
| NA1415 | Whole Exome Sequencing Panel | Next Generation Sequencing | 35 Days | neuroCORE | brain | ||||||||||
| MC1702 | DUCHENNE / BECKER MUSCULAR DYSTROPHY (DMD / BMD) GENE MUTATION | MLPA | 28 Days | neuroCORE | brain | ||||||||||
| HB1134 | Fragile-X Syndrome (FMR1 – gene dosage & methylation) | RT-PCR-CGG Repeat | 2 Weeks | neuroCORE | brain | ||||||||||
| HB1289 | Spinal cerebellar ataxia ( SCA ) - two gene | PCR | 16 Days | neuroCORE | brain | ||||||||||
| HB1282 | Spinal muscular atrophy ( SMA ) - prenatal diagnosis | PCR | 16 Days | neuroCORE | brain | ||||||||||
| HB1278 | Dystonia (DYT1,6,12,16) MLPA | MLPA | 16 Days | neuroCORE | brain | ||||||||||
| HB1277 | Ataxia Telengiectasia chromosomal analysis ( Bieomycin Assay ) | Cytogenetics | 16 Days | neuroCORE | brain | ||||||||||
| HB1276 | Neurofibromatosis type 2 NF2 22q12 MLPA | MLPA | 16 Days | neuroCORE | brain | ||||||||||
| HB1275 | Neurofibromatosis linkage ( prenatal diagnosis ) | PCR | 16 Days | neuroCORE | brain | ||||||||||
| HB1274 | Neurofibromatosis (Exon 16) | PCR | 16 Days | neuroCORE | brain | ||||||||||
| HB1269 | Duchenne muscular dystrophy ( DMD ) prenatal diagnosis | Sequencing | 16 Days | neuroCORE | brain | ||||||||||
| HB1260 | Wilson disease - prenatal diagnosis by linkage | Multiplex PCR | 16 Days | neuroCORE | brain | ||||||||||
| YB1268 | 22q deletion (N-25) | FISH | 15 Days | neuroCORE | brain | ||||||||||
| HB1261 | Joubert Syndrome -21 (exon 19 and 23) | MS-PCR | 10 Days | neuroCORE | brain | ||||||||||
| HB1131 | Congenital Muscular Dystrophy (LAMA2) deletion/duplication analysis | MLPA | 1 Weeks | neuroCORE | brain | ||||||||||
| HB1170 | 4 in 1 Genetic Screening Panel | Sangers Sequencing | 1 Week | neuroCORE | brain | ||||||||||
| HB1169 | Parkinson's Disease Panel- Familial | MLPA | 1 Week | neuroCORE | brain | ||||||||||
| HB1140 | Wilson's Disease | Multiple Technologies | 1 Week | neuroCORE | brain | ||||||||||
| HB1133 | Limb Girdle Muscular Dystrophy deletion/duplication analysis ( SGCA, SGCB, SGCD, SGCG & FKRP) | MLPA | 1 Week | neuroCORE | brain | ||||||||||
| HB1147 | VGCC Antibody- LEMS | RIA | 1 Month | neuroCORE | brain | ||||||||||
| HB1419 | Steroid-Resistant Nephrotic Syndrome | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1417 | Renal Cancer Comprehensive Panel | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1416 | Primary Hyperoxaluria | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1415 | Nephronophthisis | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1413 | Joubert and Meckel | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1412 | Polycystic Kidney Disease | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1411 | Cystinuria | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1409 | Branchiootorenal Spectrum Disorders | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1408 | Bartter Syndrome | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| HB1407 | Bardet-Biedl Syndrome | Next Generation Sequencing | 35 Days | nephroCORE | kidney | ||||||||||
| YB1445 | t (17;19) | FISH | 8 Days | hemaCORE | haematology | cancer | |||||||||
| YB1264PB | CCND1 t(11;14 translocation) | FISH | 7 Days | hemaCORE | haematology | cancer | cyclin | ||||||||
| YB1189PB | t(8;14) IGH/MYC | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1315PB | t(14;18)IGH/BCL2 | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1997 | t(11;17) Miller Dieker Syndrome | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1316PB | BCL6 t(3q27) | FISH | 7 Days | hemaCORE | haematology | cancer | B-Cell Lymphoma | ||||||||
| YB1262 | Monosomy 1 | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB2023 | Translocation (1;19) | FISH | 7 Days | hemaCORE | haematology | cancer | |||||||||
| YB1269 | Trisomy8 | FISH | 6 Days | hemaCORE | haematology | cancer | |||||||||
| PA1840 | Bone Marrow NSE Stain | Microscopy | 4 Days | hemaCORE | haematology | cancer | |||||||||
| PA1842 | Bone Marrow,MPO stain | Microscopy | 4 Days | hemaCORE | haematology | cancer | |||||||||
| PA1320 | Bone Marrow,Reticulin stain | Microscopy | 4 Days | hemaCORE | haematology | cancer | |||||||||
| PA1878 | PAS D | Microscopy | 4 Days | hemaCORE | haematology | cancer | |||||||||
| PA1883 | Trichrome (MT) | Microscopy | 4 Days | hemaCORE | haematology | cancer | |||||||||
| IA1910 | EBV IHC without Interpretation | IHC | 3 Days | hemaCORE | haematology | cancer | Epstein-Barr Virus | ||||||||
| WB2043 | Immune Deficiency Panel 1 | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| P00154 | Protein Electrophoresis Reflex immunofixation (Qualitative) | Electrophoresis | 3 Days | hemaCORE | haematology | cancer | |||||||||
| WB1626 | CD 41a | Flow Cytometry | 3 Days | hemaCORE | haematology | cancer | |||||||||
| WB2001 | Platelet Antibodies, Indirect (IgG, IgM, IgA) | Flow Cytometry | 20 Days | hemaCORE | haematology | cancer | |||||||||
| WB1897 | CD11b | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1856 | CD43 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1805 | CD58 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1664 | CD138 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1808 | CD200 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1186 | Lambda Light Chain (Clonal Restriction/B -Cell Maturity Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1187 | Kappa Light Chain (Clonal Restriction/B -Cell Maturity Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1861 | FMC - 7 (NHL / CLL Differentiation Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1799 | HLA - DR (Miscellaneous Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | human leukocyte antigen | transplant | |||||||
| WB1798 | MPO (Myeloid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1886 | Anti TCR -1 Gamma/ Delta | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | Purified anti-human TCR α/β Antibody | ||||||||
| WB1885 | Anti TCR -1 Alpha/ Beta | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | Purified anti-human TCR α/β Antibody | ||||||||
| HB443 | TdT (Precursor Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1810 | CD123 | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1006 | CD117 (Myeloid Cell Marker) / GIST Marker | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1809 | CD103 (Hairy Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1806 | CD71 (Erythroid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1804 | CD64 (Myelo Monocytic Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1690 | CD61 (Megakaryocytic Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1701 | CD38 (Plasma Cell / Prognostic CLL Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1670 | CD34 (Precursor Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1802 | CD33 (Myeloid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1136 | CD25 (Hairy Cell / NHL Differentiation Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1137 | CD22 (B - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1306 | CD16 (Natural Killer Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1669 | CD15 (Myeloid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1803 | CD14 (Monocytic Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1801 | CD13 (Myeloid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1898 | CD11c (Myeloid / Hairy Cell / NHL Differentiation Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1785 | CD10 (CALLA) Prognostic ALL Marker | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1858 | CD8 (Suppressor T - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1800 | CD7 ( T - Cell / Early Myeloid Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1132 | CD2 ( T - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1807 | CD1a (T - Cell Marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1274 | Glycophorine (CD235a) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| WB1864 | CyCD3 (T- Cell marker) | Flow Cytometry | 2 Days | hemaCORE | haematology | cancer | |||||||||
| M12082 | Chimerism, Split Cell Analysis | PCR, Fragment analysis | 17 Days | hemaCORE | haematology | cancer | |||||||||
| WB1267 | DNA Ploidy &S Phase (Leukemia) | Flow Cytometry | 15 Days | hemaCORE | haematology | cancer | |||||||||
| YB1463 | t(17;22) COL1A1/PDGFB | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1264YG | CCND1 t(11;14 translocation) | FISH | 12 Days | hemaCORE | haematology | cancer | cyclin | ||||||||
| YB1036 | 12q13 (Myxoid/Round Cell Liposarcoma) | FISH | 12 Days | hemaCORE | haematology | cancer | DDIT3 | GADD153 | |||||||
| MA2055 | FLT3/ITD allelic frequency assay | PCR | 12 Days | hemaCORE | haematology | cancer | FMS-like tyrosine kinase | ||||||||
| NA1356 | Recipient only, HLA typing (High Resolution) A & B | Next Generation Sequencing | 12 Days | hemaCORE | haematology | cancer | |||||||||
| NA1205 | Donor only, HLA typing (High Resolution) A & B | Next Generation Sequencing | 12 Days | hemaCORE | haematology | cancer | |||||||||
| NA1206 | Donor only, HLA typing (High Resolution) | Next Generation Sequencing | 12 Days | hemaCORE | haematology | cancer | |||||||||
| YB1460 | t (5:14) HOX11 | FISH | 12 Days | hemaCORE | haematology | cancer | |||||||||
| NA1459 | KIR TYPING (per individual) | NGS (High Resolution) | 12 Days | hemaCORE | haematology | cancer | |||||||||
| EB615 | Cytogenetics (Karyotyping), BCR-Abl Qual (RT-PCR) | As mentioned in individual tests | 12 Days | hemaCORE | haematology | cancer | |||||||||
| MM1006PB | c-KIT: AML | Mutation Analysis | 10 Days | hemaCORE | haematology | cancer | Acute myeloid leukemia | ||||||||
| TS597 | LBC (Cytology)+HPV DNA (RT-PCR)+E6-E7 | As mentioned in individual tests | 5 Days | gynaeCORE | liquid | papilloma | sexual | reproductive | gynaecology | ||||||
| CA1185 | LBC with out opinion | Cytology | 2 Days | gynaeCORE | liquid | sexual | reproductive | gynaecology | |||||||
| YB1266 | X Y Chromosome | FISH | 15 Days | gynaeCORE | gynaecology | ||||||||||
| YB1421 | Trisomy 21 / Down syndrome | FISH | 10 Days | gynaeCORE | gynaecology | ||||||||||
| HB1353 | Zellweger Syndrome | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1352 | Xeroderma Pigmentosum | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1348 | Usher Syndrome | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1344 | Retinitis Pigmentosa | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1337 | Glaucoma | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1336 | Flecked Retina | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1334 | Congenital Cataracts | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1333 | Cone-Rod Dystrophy | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1331 | Ciliopathies | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1330 | Bardet-Biedl Syndrome | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1329 | Ataxia with Oculomotor Apraxia Type 1/2 | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1328 | Alport Syndrome | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| HB1326 | Achromatopsia | Next Generation Sequencing | 35 Days | eyeCORE | opthaophthalmology | opthal | ophthalmic | ||||||||
| XA1952 | T3, REVERSE | LC/MS/MS | Sample By 7Th Of The Month; Report After 2-3 Weeks | endoCORE | endocrine | endocrinology | |||||||||
| HB1158 | Diabetes Progression Panel | Real Time AS-PCR | 8 Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1157 | Overweight and Obesity Panel | Real Time AS-PCR | 8 Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1153 | geneCORE Nutrient | Next Generation Sequencing | 6 Weeks | endoCORE | endocrine | endocrinology | |||||||||
| HB1161 | Statin Tolerance | Real Time AS-PCR | 6 Days | endoCORE | endocrine | endocrinology | |||||||||
| MV1943 | RET Gene mutation for 6 exons | Sangers Sequencing | 5 Weeks | endoCORE | endocrine | endocrinology | |||||||||
| HB1364 | Premature Ovarian Failure | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1363 | Kallmann Syndrome Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1362 | Hypothyroidism and Resistance to Thyroid Hormone Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1361 | Hypomagnesemia Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1360 | Hypoglycemia, Hyperinsulinism and Ketone Metabolism Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1359 | Hyperparathyroidism Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1358 | Glucocorticoid Deficiency Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1357 | Congenital Adrenal Hyperplasia Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1356 | Fatty Acid Oxidation Disorders Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1355 | Comprehensive Monogenic Diabetes Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1354 | Abnormal Genitalia/ Disorders of Sex Development Panel | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| NA1565 | Leptin Gene, Sequencing & Deletion/Duplication | Next Generation Sequencing | 35 Working Days | endoCORE | endocrine | endocrinology | |||||||||
| MN1402 | PPARG, Full Gene Sequencing | Next Generation Sequencing | 35 Days | endoCORE | endocrine | endocrinology | |||||||||
| NA2088 | POMC, Full Gene Sequencing | Next Generation Sequencing | 35 Days | endoCORE | endocrine | endocrinology | |||||||||
| NA1398 | obeCORE Monogenic Obesity | Next Generation Sequencing | 35 Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1156 | Maturity Onset Diabetes of the Young (MODY) | Next Generation Sequencing | 35 Days | endoCORE | endocrine | endocrinology | |||||||||
| HB1155 | Hypoglycemia, Hyperinsulinism and Ketone Metabolism Panel | Next Generation Sequencing | 35 Days | endoCORE | endocrine | endocrinology | |||||||||
| AB1826 | Anti Thyroid Antibodies panel | Chemiluminescent Immunoassay | 3 Days | endoCORE | endocrine | endocrinology | |||||||||
| AB1255 | Anti Thyroglobulin Antibody; ANTI Tg | Chemiluminescent Microparticle Immunoassay (CMIA) | 1 Day | endoCORE | endocrine | endocrinology | |||||||||
| HB1402 | Warfarin Sensitivity | Real Time AS-PCR | 6 Days | cardioCORE | Cardiology | Cardiac | heart | anticoagulant | |||||||
| HB1400 | Thrombophillia 3- gene | Real Time AS-PCR | 6 Days | cardioCORE | Cardiology | Cardiac | heart | clots | |||||||
| HB1398 | Clopidogrel Sensitivity | Real Time AS-PCR | 6 Days | cardioCORE | Cardiology | Cardiac | heart | antiplatelet | CYP2C19 | ||||||
| HB1397 | Anti- Hypertensives Response Panel | Real Time AS-PCR | 6 Days | cardioCORE | Cardiology | Cardiac | heart | hypertension | |||||||
| HB1390 | Familial Hyperlipidemia type III | Real Time AS-PCR | 6 Days | cardioCORE | Cardiology | Cardiac | heart | lipid | |||||||
| HB1396 | Comprehensive Cardiovascular Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | coronary artery disease | coronary | pressure | arrest | heart failure | stroke | congenital | |
| HB1394 | Hereditary Heart Health Test | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1393 | Heterotaxy and Situs Inversus Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | atrial | appendages | situs solitus | |||||
| HB1392 | Noonan and RASopathies Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1391 | Congenital Heart Diseases Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | valve | heart wall | blood vessel | Cyanotic | Acyanotic | |||
| HB1387 | Familial Hypercholesterolemia (FH) Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | cholesterol | |||||||
| HB1386 | Capillary Malformation-Arteriovenous Malformation Syndrome Test | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1385 | Hereditary Hemorrhagic Telangiectasia Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | haemorrhage | telangiectases | vessel | spider veins | ||||
| HB1384 | Pulmonary Arterial Hypertension (PAH) Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1383 | Loeys-Dietz syndrome | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | loeys | dietz | marfan | aortic | aneurysms | |||
| HB1382 | Ehlers-Danlos syndrome, | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | connective tissue | |||||||
| HB1381 | Marfan/TAAD Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | Marfan | thoracic | aortic | aneurysm | dissection | |||
| HB1379 | Heritable Disorders of Connective Tissue Panel (HDCT Panel) | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1378 | Combined Cardiac Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1377 | Brugada Syndrome Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | rhythm | |||||||
| HB1376 | CPVT Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | Catecholaminergic | polymorphic | ventricular | tachycardia | arrhythmia | |||
| HB1374 | Arrhythmia Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | irregular | heartbeat | ||||||
| HB1373 | LQTS Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | long | qt | ||||||
| HB1372 | SQTS Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | short | qt | ||||||
| HB1371 | Familial Atrial Fibrillation Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | rhythm | |||||||
| HB1370 | SCA Arrhythmia Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1369 | Cardiomyopathy Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | ||||||||
| HB1368 | ARVC Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | Arrhythmogenic | ventricular | cardiomyopathy | |||||
| HB1367 | HCM Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | Hypertrophic | cardiomyopathy | ||||||
| HB1366 | LNVC Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | left | ventricular | non-compaction | |||||
| HB1365 | DCM Panel | Next Generation Sequencing | 4 Weeks | cardioCORE | Cardiology | Cardiac | heart | cardiomyopathy | dilated | enlarged | |||||
| EB703 | Corus CAD | Next Generation Sequencing | 10 Days | cardioCORE | Cardiology | Cardiac | heart | coronary artery disease | coronary | blockage | angio | non-invasive |
Book a Confidential Appointment with one of our Genetic Experts
Our consultation service is available in several languages.
